摘要
目的观察罗格列酮应用于单用胰岛素治疗血糖控制欠佳的2型糖尿病患者的疗效及安全性。方法80例2型糖尿病患者随机分成两组:单用胰岛素治疗组(DM+INS组)40例、联合治疗组(DM+INS+RSG组)40例,在继续应用胰岛素治疗的基础上加服罗格列酮4mg/d,共3个月。观测两组治疗前后空腹血糖及餐后血糖、糖化血红蛋白、甘油三酯、胆固醇、高密度脂蛋白、低密度脂蛋白和体重指数的改变。结果DM+INS+RSG组与DM+INS组治疗前FPG、PPG、HbA1C、TC、TG、HDL-C、LDL-C和胰岛素用量无明显统计学差异(P>0.05)。DM+INS+RSG组治疗后1个月和3个月FPG、PPG、HbA1C均有明显的下降(P<0.05,P<0.01)。结论对单用胰岛素治疗血糖控制欠佳的2型糖尿病患者,可加用胰岛素增敏剂罗格列酮治疗,使血糖和糖化血红蛋白得以良好的控制。
Objective To observe the efficacy and safety of rosiglitazone combined with insulin in the treatment of type 2 diabetic patients who were not good control in plasma glucose on insulin monotherapy. Methods 80 type 2 diabetic patients were randomized into insulin monotherapy group（DM ＋ INS group） 40 cases and rosiglitazone and insulin group（DM ＋ INS ＋ RSG group） 40 cases for 3 months treatment. The dosage of rosiglitazone was given 4mg everyday in DM ＋ INS ＋ RSG group. The changes of laboratory data including fasting plasma glucose （FPG）, postprandial plasma glucose （PPG）, hemolobulin A 1C （HbA 1C ）, cholesteral （TC）, triglyceride （TG）, high density lipoprotein-cholesteral （HDL-C）,low density lipoprotein cholesterol （LDL-C）, body mass index （BMI） was measured before and after treatment in different groups. Results There was not significantly difference in FPG,PPG,HbA1C,TC,TG,HDL-C,LDL-C and dosages of insulin in the baselin between DM ＋ INS group and DM ＋ INS ＋ RSG group （P 〉 0.05）. There was significantly decrease in FPG, PPG and HbA1C in the DM ＋ INS ＋ RSG group after 1 and 3 months treatment（P 〈 0.05 ,P 〈 0.01 ）. Conclusion The addition of rosglitazone and insulin can improve the efficacy in glycemic control in the type 2 diabetic patients.
出处
《中国现代医生》
2008年第13期4-5,19,共3页
China Modern Doctor
关键词
糖尿病
胰岛素
罗格列酮
2型
疗效
Diabetes mellitus
Insulin
Rosiglitazone
Type 2
Efficacy
